deltatrials
Unknown PHASE2 INTERVENTIONAL 3-arm NCT05950152

Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of Meloxicam Injection in Subjects After Abdominal Surgery

Sponsor: Beijing Tide Pharmaceutical Co., Ltd

Updated 4 times since 2023 Last updated: Jul 10, 2023 Started: Jul 31, 2023 Primary completion: Dec 31, 2023 Completion: Feb 29, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pain, Post-operative and is currently ongoing. Beijing Tide Pharmaceutical Co., Ltd leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshotNot Yet Recruiting~Aug 2025 – present · 13 months · monthly snapshotUnknown

Change History

4 versions recorded
  1. Aug 2025 — Present [monthly]

    Unknown PHASE2

    Status: Not Yet RecruitingUnknown

  2. Sep 2024 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  4. Aug 2023 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Jul 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Tide Pharmaceutical Co., Ltd
  • The Third Xiangya Hospital of Central South University
Data source: Beijing Tide Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations